The authors of this review remind readers that there are currently no disease-modifying therapies for Dementia with Lewy bodies (DLB). DLB accounts for perhaps 25% of all dementia cases.
This review covers therapeutic directions which have been explored for the treatment of DLB. Approaches, so far, have involved investigating the therapeutic potential of (i) strategies to decrease the level of alpha-synuclein, (ii) strategies to prevent cell-to-cell transmission of misfolded alpha-synuclein, and (iii) brain stimulation for DLB.
Zhang, Q. Kim, YC. [and] Narayanan, NS. (2015). Disease-modifying therapeutic directions for Lewy-Body dementias. Frontiers in Neuroscience. August 20th 2015, Vol.9, 293. (Click here to view the PubMed abstract).